Doctors treating children with a rare and severe form of epilepsy were stunned by the news. A crucial drug, H.P. Acthar Gel, that had been selling for $1,600 a vial would now cost $23,000.

The price increase, put in place over last Labor Day weekend, also jolted employers that provide health benefits to their workers and bear the brunt of drug costs.

As it turned out, the exclusive distributor of H.P. Acthar Gel is Express Scripts, a company whose core business is supposed to be helping employers manage their drug insurance programs and get medicines at the best available prices.

But in recent years, drug benefit managers like Express Scripts have built lucrative side businesses seemingly at odds with that best-price mission. A growing portion of their revenue comes from acting as exclusive or semi-exclusive distributors of expensive specialty drugs that can cost thousands of dollars. And the prices of such medicines are rising much faster than for the mainstream prescription drugs available through a wide variety of distributors.

more:Benefit Managers Profit by Specialty Drug Rights – New York Times

Comments

Leave a Reply




  •  

     

     

     

  •  

     

     

  • Important Notice

    This site posts excerpts and summaries of articles of interest to people with multiple sclerosis and their families, along with links to the full articles in the journals in which they were published.

    I have multiple sclerosis (primary progressive), but I am neither a doctor nor a research scientist. I have no connection to the people mentioned in these articles, and have no more information about the subject of any given article than is contained in the article itself. Please do not ask me for medical advice or how to contact people mentioned in these articles. If contact information is not contained in the article itself, your best bet is to Google the name of the person, company or clinic you are seeking.